PDCD1 and hepatocellular carcinoma: HAIC combined with lenvatinib + PD-1 inhibitor was also superior to TACE combined with lenvatinib + PD-1 inhibitor in patients with advanced HCC combined with portal vein tumor thrombosis and portal arteriovenous fistulae (3).